Purpose: To describe a case of retinal vaso-occlusive vasculitis with associated lid edema and conjunctivitis following intravitreal pegcetacoplan administration in a patient with geographic atrophy (GA).

Observation: A 78 year old Caucasian woman presented with complaints of lid edema, conjunctival injection, loss of vision, and mild ocular discomfort eleven days after receiving an intravitreal pegcetacoplan injection in the left eye for geographic atrophy. Visual acuity on presentation was decreased to 20/400 from 20/200 previously in that eye. Eyelid edema and conjunctival injection were present with minimal anterior chamber reaction. Dilated fundus examination revealed hemorrhages throughout the retina and signs of retinal vasculitis. The patient subsequently developed hyphema and vitreous hemorrhage. Laboratory evaluations for common infectious and inflammatory causes including aqueous and vitreous cultures for bacteria and Herpes simplex PCR were normal or negative. A delayed hypersensitivity to pegcetacoplan was suspected and was treated with topical, oral subconjunctival and intravitreal steroids.

Conclusion: This index report illustrates a case of retinal vaso-occlusive vasculitis associated with intravitreal pegcetacoplan associated with lid edema and conjunctival injection and subsequent hyphema and vitreous hemorrhage. Therapy with steroids topically, systemically, periocularly and intravitreally were used to treat the inflammatory process and prevent further visual loss.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10828598PMC
http://dx.doi.org/10.1016/j.ajoc.2024.101999DOI Listing

Publication Analysis

Top Keywords

intravitreal pegcetacoplan
16
lid edema
12
edema conjunctival
12
conjunctival injection
12
retinal vasculitis
8
pegcetacoplan administration
8
case retinal
8
retinal vaso-occlusive
8
vaso-occlusive vasculitis
8
vasculitis associated
8

Similar Publications

Recent developments in treatments for both forms of advanced age-related macular degeneration (AMD) have led to the approval of multiple agents and modalities within the last few years. Five new medications for both neovascular AMD (nAMD) and geographic atrophy (GA) secondary to nonexudative AMD (neAMD) have been FDA-approved within the last 5 years, along with a new device designed for sustained drug delivery for nAMD. In nAMD, the newest agents approved by the FDA are brolucizumab (Novartis Pharmaceuticals, Basel, Switzerland), faricimab (F.

View Article and Find Full Text PDF
Article Synopsis
  • Geographic atrophy (GA) is a severe form of dry age-related macular degeneration characterized by well-defined areas of retinal damage, with growing evidence linking the complement system's overactivation to its progression.
  • New FDA-approved treatments like SYFOVRE™ and IZERVAY™ focus on inhibiting this complement system to potentially slow down GA development.
  • Gene therapy is emerging as a novel approach, aiming to introduce new genes into the eye to enhance protein production or create beneficial substances, ultimately targeting the root causes of GA.
View Article and Find Full Text PDF

To describe a case of endophthalmitis caused by , an encapsulated bacterium, after intravitreal (IVT) injection of pegcetacoplan. A single retrospective case was evaluated. An 88-year-old woman with a history of diabetes mellitus, on dialysis for chronic kidney disease, hypertension, hypothyroidism, diffuse large B-cell lymphoma, and geographic atrophy in both eyes received an IVT injection of pegcetacoplan in both eyes.

View Article and Find Full Text PDF

Pegcetacoplan is a complement C3/C3b inhibitor indicated for the treatment of geographic atrophy (GA). A population pharmacokinetic (PK)/pharmacodynamic (PD) analysis of pegcetacoplan used GA lesion area measurements from three clinical studies to determine the effect of pegcetacoplan exposure on GA progression. A base disease progression model was developed using data from sham-treated eyes and untreated fellow eyes, followed by treatment effect assessment in dose-response and PK/PD models.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!